29.66 USD
+0.06 (+0.2%)
29.75 USD
+0.09 (+0.3%)
ALKS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. ALKS gets an excellent profitability rating and is at the same time showing great financial health properties. ALKS has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ALKS was profitable.
In the past year ALKS had a positive cash flow from operations.
In multiple years ALKS reported negative net income over the last 5 years.
Each year in the past 5 years ALKS had a positive operating cash flow.
1.2 Ratios
ALKS's Return On Assets of 14.57% is amongst the best of the industry. ALKS outperforms 95.28% of its industry peers.
Looking at the Return On Equity, with a value of 19.58%, ALKS belongs to the top of the industry, outperforming 96.04% of the companies in the same industry.
ALKS's Return On Invested Capital of 16.22% is amongst the best of the industry. ALKS outperforms 96.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.57% | ||
| ROE | 19.58% | ||
| ROIC | 16.22% |
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 22.30%, ALKS belongs to the best of the industry, outperforming 94.34% of the companies in the same industry.
ALKS's Operating Margin of 23.59% is amongst the best of the industry. ALKS outperforms 95.66% of its industry peers.
ALKS's Gross Margin of 86.04% is amongst the best of the industry. ALKS outperforms 88.68% of its industry peers.
In the last couple of years the Gross Margin of ALKS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 22.3% | ||
| GM | 86.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ALKS is creating value.
Compared to 1 year ago, ALKS has less shares outstanding
Compared to 5 years ago, ALKS has more shares outstanding
There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ALKS has an Altman-Z score of 6.27. This indicates that ALKS is financially healthy and has little risk of bankruptcy at the moment.
ALKS has a better Altman-Z score (6.27) than 75.09% of its industry peers.
There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.27 |
ROIC/WACC2.11
WACC7.7%
2.3 Liquidity
A Current Ratio of 3.67 indicates that ALKS has no problem at all paying its short term obligations.
The Current ratio of ALKS (3.67) is comparable to the rest of the industry.
A Quick Ratio of 3.27 indicates that ALKS has no problem at all paying its short term obligations.
The Quick ratio of ALKS (3.27) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.67 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.71% over the past year.
ALKS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 32.50% yearly.
Looking at the last year, ALKS shows a small growth in Revenue. The Revenue has grown by 1.08% in the last year.
Measured over the past years, ALKS shows a small growth in Revenue. The Revenue has been growing by 5.87% on average per year.
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
3.2 Future
Based on estimates for the next years, ALKS will show a decrease in Earnings Per Share. The EPS will decrease by -1.55% on average per year.
The Revenue is expected to grow by 7.72% on average over the next years.
EPS Next Y-48.04%
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
EPS Next 5Y-1.55%
Revenue Next Year-2.41%
Revenue Next 2Y10.1%
Revenue Next 3Y6.85%
Revenue Next 5Y7.72%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 11.96, the valuation of ALKS can be described as very reasonable.
97.36% of the companies in the same industry are more expensive than ALKS, based on the Price/Earnings ratio.
ALKS's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.19.
With a Price/Forward Earnings ratio of 19.48, ALKS is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ALKS is valued cheaper than 94.15% of the companies in the same industry.
ALKS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.96 | ||
| Fwd PE | 19.48 |
4.2 Price Multiples
ALKS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALKS is cheaper than 97.55% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ALKS is valued cheaper than 98.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.97 | ||
| EV/EBITDA | 8.46 |
4.3 Compensation for Growth
The decent profitability rating of ALKS may justify a higher PE ratio.
A cheap valuation may be justified as ALKS's earnings are expected to decrease with -19.20% in the coming years.
PEG (NY)N/A
PEG (5Y)0.37
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
5. Dividend
5.1 Amount
No dividends for ALKS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
29.66
+0.06 (+0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.82%
Inst Owner Change0.01%
Ins Owners1.48%
Ins Owner Change-0.47%
Market Cap4.90B
Revenue(TTM)1.52B
Net Income(TTM)339.32M
Analysts80.87
Price Target44.75 (50.88%)
Short Float %12.37%
Short Ratio8.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.1%
Min EPS beat(2)59.84%
Max EPS beat(2)72.36%
EPS beat(4)4
Avg EPS beat(4)43.68%
Min EPS beat(4)12.02%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)10.27%
EPS beat(12)8
Avg EPS beat(12)42.89%
EPS beat(16)11
Avg EPS beat(16)151.46%
Revenue beat(2)2
Avg Revenue beat(2)10.32%
Min Revenue beat(2)8.51%
Max Revenue beat(2)12.13%
Revenue beat(4)3
Avg Revenue beat(4)7.62%
Min Revenue beat(4)-1.19%
Max Revenue beat(4)12.13%
Revenue beat(8)4
Avg Revenue beat(8)3.11%
Revenue beat(12)7
Avg Revenue beat(12)3.8%
Revenue beat(16)10
Avg Revenue beat(16)3.09%
PT rev (1m)0%
PT rev (3m)4.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.27%
EPS NY rev (1m)0%
EPS NY rev (3m)16.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.96 | ||
| Fwd PE | 19.48 | ||
| P/S | 3.22 | ||
| P/FCF | 9.97 | ||
| P/OCF | 9.06 | ||
| P/B | 2.83 | ||
| P/tB | 2.97 | ||
| EV/EBITDA | 8.46 |
EPS(TTM)2.48
EY8.36%
EPS(NY)1.52
Fwd EY5.13%
FCF(TTM)2.98
FCFY10.03%
OCF(TTM)3.27
OCFY11.04%
SpS9.21
BVpS10.5
TBVpS9.99
PEG (NY)N/A
PEG (5Y)0.37
Graham Number24.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.57% | ||
| ROE | 19.58% | ||
| ROCE | 19.34% | ||
| ROIC | 16.22% | ||
| ROICexc | 40.45% | ||
| ROICexgc | 45.58% | ||
| OM | 23.59% | ||
| PM (TTM) | 22.3% | ||
| GM | 86.04% | ||
| FCFM | 32.29% |
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 163.07% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 138.93% | ||
| Profit Quality | 144.77% | ||
| Current Ratio | 3.67 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 6.27 |
F-Score6
WACC7.7%
ROIC/WACC2.11
Cap/Depr(3y)76.88%
Cap/Depr(5y)63.55%
Cap/Sales(3y)2.83%
Cap/Sales(5y)2.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
EPS Next Y-48.04%
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
EPS Next 5Y-1.55%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
Revenue Next Year-2.41%
Revenue Next 2Y10.1%
Revenue Next 3Y6.85%
Revenue Next 5Y7.72%
EBIT growth 1Y-17.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.47%
EBIT Next 3Y5.58%
EBIT Next 5Y14.79%
FCF growth 1Y93.4%
FCF growth 3Y76.56%
FCF growth 5YN/A
OCF growth 1Y83.22%
OCF growth 3Y62.84%
OCF growth 5Y43.53%
ALKERMES PLC / ALKS FAQ
What is the fundamental rating for ALKS stock?
ChartMill assigns a fundamental rating of 6 / 10 to ALKS.
What is the valuation status of ALKERMES PLC (ALKS) stock?
ChartMill assigns a valuation rating of 6 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.
Can you provide the profitability details for ALKERMES PLC?
ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.
Can you provide the expected EPS growth for ALKS stock?
The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -48.04% in the next year.